Cargando…

Apatinib as targeted therapy for sarcoma

Sarcomas are a group of malignant tumors originating from mesenchymal tissue with a variety of cell subtypes. Despite several major treatment breakthroughs, standard treatment using surgery, radiation, and chemotherapy has failed to improve overall survival. Therefore, there is an urgent need to exp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Feng, Liao, Zhichao, Zhang, Chao, Zhao, Jun, Xing, Ruwei, Teng, Sheng, Zhang, Jin, Yang, Yun, Yang, Jilong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966248/ https://www.ncbi.nlm.nih.gov/pubmed/29849960 http://dx.doi.org/10.18632/oncotarget.24647

Ejemplares similares

Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy
por: Liao, Zhichao, et al.
Publicado: (2020)

Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety
por: Liao, Zhichao, et al.
Publicado: (2019)

Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China
por: Li, Feng, et al.
Publicado: (2017)

Clinicopathologic features, prognostic factors, and outcomes of visceral sarcomas: A retrospective 12-year single-center study
por: Yang, Songwei, et al.
Publicado: (2022)

Chemotherapy Combined With Recombinant Human Endostatin (Endostar) Significantly Improves the Progression-Free Survival of Stage IV Soft Tissue Sarcomas
por: Liao, Zhichao, et al.
Publicado: (2022)

The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma
por: Lu, Jia, et al.
Publicado: (2022)

Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV
por: Xing, Peipei, et al.
Publicado: (2016)

Outcomes of surgery and/or combination chemotherapy for extraskeletal osteosarcoma: a single-center retrospective study from China
por: Liao, Zhichao, et al.
Publicado: (2019)

Apatinib for molecular targeted therapy in tumor
por: Zhang, Haijun
Publicado: (2015)

Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study
por: Tian, Zhichao, et al.
Publicado: (2021)

Therapeutic perspectives for adult soft tissue sarcoma—updates from the 2022 ASCO annual meeting
por: Yang, Jilong, et al.
Publicado: (2022)

Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions
por: Tian, Zhichao, et al.
Publicado: (2019)

A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019)

Advanced alveolar soft part sarcoma responds to apatinib
por: Zhou, Yong, et al.
Publicado: (2017)

The new horizon of liquid biopsy in sarcoma: the potential utility of circulating tumor nucleic acids
por: Wei, Junqiang, et al.
Publicado: (2020)

Pan-Soft Tissue Sarcoma Analysis of the Incidence, Survival, and Metastasis: A Population-Based Study Focusing on Distant Metastasis and Lymph Node Metastasis
por: Liu, Haotian, et al.
Publicado: (2022)

Clinicopathological features of pseudomyogenic hemangioendothelioma and precision therapy based on whole exome sequencing
por: Wei, Junqiang, et al.
Publicado: (2020)

Effective Treatment of Low-Grade Myofibroblastic Sarcoma with Apatinib: A Case Report and Literature Review
por: Lin, Yan, et al.
Publicado: (2022)

Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study
por: Wang, Jiaqiang, et al.
Publicado: (2021)

A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma
por: Zhang, Chao, et al.
Publicado: (2022)

The use of apatinib in treating primary pleural synovial sarcoma: A case report
por: Chen, Sumei, et al.
Publicado: (2019)

Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial
por: Yu, Wenxi, et al.
Publicado: (2022)

Apatinib as an optional treatment in metastatic colorectal cancer
por: Li, Aiyi, et al.
Publicado: (2019)

Targeted Therapy in Ewing Sarcoma
por: Lissat, A., et al.
Publicado: (2012)

Treatment of uterine high-grade endometrial stromal sarcoma with apatinib combined with chemotherapy: A case report
por: Zhang, Ying, et al.
Publicado: (2019)

Roles of low-density lipoprotein receptor-related protein 1 in tumors
por: Xing, Peipei, et al.
Publicado: (2016)

Apatinib as an alternative therapy for advanced hepatocellular carcinoma
por: Zhang, Xi-Hao, et al.
Publicado: (2020)

Targeted therapy with apatinib in a patient with relapsed small cell lung cancer: A case report and literature review
por: Zhao, Jun, et al.
Publicado: (2017)

A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas
por: Zhou, Yan, et al.
Publicado: (2023)

Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study
por: Wang, Jiaqiang, et al.
Publicado: (2023)

Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study
por: Liang, Jianmiao, et al.
Publicado: (2020)

Targeted therapy for sarcomas
por: Forscher, Charles, et al.
Publicado: (2014)

The efficacy and safety of apatinib in Ewing’s sarcoma: a retrospective analysis in one institution
por: Wang, Yitian, et al.
Publicado: (2018)

Progress in the treatment of solid tumors with apatinib: a systematic review
por: Zhao, Deze, et al.
Publicado: (2018)

Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study
por: Tian, Zhichao, et al.
Publicado: (2019)

Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma
por: Yang, Chaoxu, et al.
Publicado: (2018)

Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China
por: Xie, Lu, et al.
Publicado: (2018)

Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review
por: Tian, Zhichao, et al.
Publicado: (2021)

Postoperative Adjuvant Radiotherapy Can Delay the Recurrence of Desmoid Tumors After R0 Resection in Certain Subgroups
por: Yang, Tielong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0kbofsecn50nnkhb6g576tkuni